C3G and Primary IC-MPGN: A Call to Action for Accurate Diagnosis and Early Management - CME - Guideline Central

CME

Title
C3G and Primary IC-MPGN: A Call to Action for Accurate Diagnosis and Early Management
Link
Description
The rare kidney disorders complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) have heterogeneous and non-specific presentations, making diagnosis and early intervention challenging for clinicians. Join a panel of expert nephrologists to review the burden of these complement-mediated kidney diseases and the role of complement pathway dysregulation in disease progression and learn strategies for ensuring timely and accurate diagnosis. Hear the latest on efficacy and safety data for new and emerging therapies and how targeting complement can slow disease progression and improve kidney survival.
Target Audience
The primary target audience for this activity are nephrologists and specialty NPs and PAs
Learning Objectives
  • Summarize the uncontrolled alternative complement cascade leading to glomerulus injury
  • Discuss disease burden, prognosis, and emerging prognostic biomarkers for C3G and primary IC-MPGN
  • Describe best practices to establish a diagnosis of C3G and primary IC-MPGN
  • Review data on the safety and efficacy of emerging agents targeting the dysregulated alternative complement pathway on proteinuria, eGFR, and select biomarkers of complement activation among adolescents and adults with native or post-transplant disease
Estimated Duration
60 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Nephrology
Keywords
primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), complement 3 glomerulopathy (C3G)
Disclosures and Disclaimers
Disclosures: All relevant financial relationships for anyone with the ability to control the content of this educational activity have been mitigated. Disclaimer: Content is current as of the date this activity was released. The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
Accredited Providers
  • Partners for Advancing Clinical Education
  • MedliveCME
  • National Organization for Rare Disorders
  • Kidney Disease Improving Global Outcomes (KDIGO)
Commercial Support
  • Apellis
Activity Expiration Date
September 26, 2026
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.